US 8987228
Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis
granted A61KA61K31/7076A61P
Quick answer
US patent 8987228 (Pharmaceutical composition including an A3 adenosine receptor agonist 1-deooxy-1-[N6-(3-idobenzyl)-adenin-9-yl]-N-methyl-β-D-ribofuronamide(IB-MECA/CF-101) for treatment of psoriasis) held by CAN-FITE BIOPHARMA LTD. expires Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CAN-FITE BIOPHARMA LTD.
- Grant date
- Tue Mar 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 12
- CPC classes
- A61K, A61K31/7076, A61P, A61P17/06